Clene (NASDAQ: CLNN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.190 | -0.210 | -0.0200 | ||||
REV | 120.000K | 30.000K | -90.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Clene (NASDAQ: CLNN) through any online brokerage.
Other companies in Clene’s space includes: Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Immuneering (NASDAQ:IMRX), Atossa Therapeutics (NASDAQ:ATOS) and Sesen Bio (NASDAQ:SESN).
The latest price target for Clene (NASDAQ: CLNN) was reported by Canaccord Genuity on Monday, May 2, 2022. The analyst firm set a price target for 10.00 expecting CLNN to rise to within 12 months (a possible 293.70% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Clene (NASDAQ: CLNN) is $2.54 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Clene.
Clene’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Clene.
Clene is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.